§ Claim under review · Mixed
"Researchers at the Babraham Institute demonstrated that certain aging markers in human skin cells can be reversed via epigenetic resetting/partial reprogramming, making the cells exhibit younger molecular and epigenetic behavior without losing their identity as skin cells." Accompanying on-image text: "Researchers can now turn the skin of a 60-year-old person back to that of a 30-year-old" + "how to slow down aging in just 12 weeks? check my bio link" + a link to a 2025 Cell paper.
Verdict
Source exists but framing is misleading
Confidence
HighSummary
The underlying research is real. In 2022, scientists at the UK's Babraham Institute reported that briefly exposing human skin cells to reprogramming factors reversed roughly 30 years of molecular and epigenetic aging markers while the cells still behaved as skin cells rather than turning into stem cells. But the post's headline goes well past that. The experiment was done on cells in a laboratory dish, not on anyone's skin, and it produced no visible or cosmetic change, so before and after skin photos are not supported by the study. The post also links to a different 2025 paper from Altos Labs and the Salk Institute, not the Babraham study it describes, and it presents 2022 work as current news. Outside experts have noted the technique is essentially a form of gene therapy that is not usable in people as it stands, with unresolved cancer risk. The "slow down aging in 12 weeks, check my bio link" product pitch has no connection to this research at all.
The readings
key figures from the evidenceduration of Yamanaka factor exposure in MPTR method
duration of full stem cell reprogramming process
molecular age reversal reported by secondary source (vs headline 30 years)
Why this verdict
Evidence
The underlying study is real and the attribution to Babraham is correct. Babraham Institute researchers developed a method to "time jump" human skin cells by 30 years, turning back the ageing clock for cells without losing their specialised function, partly restoring the function of older cells as well as rejuvenating molecular measures of biological age .
The mechanism matches the caption's description. While the full process of stem cell reprogramming takes around 50 days using four Yamanaka factors, maturation phase transient reprogramming exposes cells to those factors for just 13 days, at which point age-related changes are removed and the cells have temporarily lost their identity; the scientists then gave the partly reprogrammed cells time to grow under normal conditions to observe whether skin cell function returned . Genome analysis showed the cells had regained markers characteristic of fibroblasts, confirmed by observing collagen production .
The authors themselves framed the finding as separating rejuvenation from full pluripotency. They concluded that it is possible to separate rejuvenation from complete pluripotency reprogramming, which should facilitate the discovery of novel anti-aging genes and therapies .
Critically, the linked reference does not match the claimed source. The Cell paper cited in the post (S0092-8674(25)00853-0) is "Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming," authored by Jinlong Y. Lu, William B. Tu and colleagues at the San Diego Institute of Science, Altos Labs, and the Salk Institute, with Juan Carlos Izpisua Belmonte as corresponding author . That paper is about a different phenomenon: analysis of gene expression data from over 40 human tissues and 20 diseases revealing pervasive upregulation of mesenchymal genes across multiple cell types, with Yamanaka factor-induced partial reprogramming markedly reducing mesenchymal drift before dedifferentiation and gain of pluripotency . It is not the Babraham study and does not involve the Babraham team.
Findings
✓ What's accurate 6
- The Babraham Institute study exists, is peer-reviewed, and is correctly attributed to that institution.
- Partial/transient reprogramming did reverse molecular and epigenetic markers of age in cultured human skin cells.
- The cells did regain fibroblast identity rather than becoming stem cells, which is the specific novelty the caption emphasises.
- Collagen production and some functional wound-healing behaviour improved.
- "Epigenetic resetting" is a fair plain-language description: the intervention changes gene regulation patterns, not the DNA sequence itself.
- Partial reprogramming is genuinely an active area of rejuvenation research, as the separate 2025 Cell paper confirms.
≈ What's misleading 7
- **Exaggeration / category error:** The on-image headline "turn the skin of a 60-year-old back to that of a 30-year-old" is not what was shown. The experiment rejuvenated isolated fibroblasts in a laboratory dish by molecular measures. No person's skin was treated, and no visible skin change was demonstrated.
- **Visual manipulation:** Before/after imagery implying visible facial or skin de-aging has no basis in the study, which produced no cosmetic or clinical outcome of any kind.
- **Citation mismatch / attribution error:** The paper linked is a 2025 Altos Labs and Salk paper on mesenchymal drift, not the 2022 Babraham eLife paper the caption describes. Readers who click the reference will not find the study being described.
- **Temporal overreach and date mismatch:** The work is presented as current news. It was published in April 2022 and framed by the institute itself as early stage.
- **Omitted qualifier:** The post omits that this is a gene-therapy-style technique, untested in living humans, with unresolved cancer and identity-loss risks, and that functional improvement was inconsistent across samples.
- **Marketing as evidence:** The "how to slow down aging in just 12 weeks, check my bio link" call to action attaches a commercial product to unrelated laboratory research. Nothing in the Babraham work involves a 12-week protocol, a consumer product, or any topical or ingestible intervention.
- **Overstated certainty:** "Proved," "most exciting advancement of the decade," and "regarded by many experts as one of the most promising steps" are promotional framings, not statements found in the study.
? What's uncertain 4
- The exact donor ages in the study cohort were not confirmed from the primary text in this investigation. Secondary sources describe them as middle-aged; one low-quality secondary source cites a 53-year-old donor, which I could not verify against the paper.
- Whether all aging hallmarks (for example telomere length) were reversed was not confirmed from the primary paper. Reported rejuvenation is specific to methylation clocks, transcriptome measures, and selected functional assays.
- Whether the Instagram account intended the Cell 2025 link as the source for the Babraham claim or as generic topical support cannot be determined.
- The identity, evidence base, and nature of the product promoted in the bio link cannot be assessed from the post.
Sources
5 of 6 linked to recordsGill et al., "Multi-omic rejuvenation of human cells by maturation phase transient reprogramming," eLife 11:e71624 (2022)
Babraham Institute press release, "A jump through time," 8 April 2022
Lu et al., "Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming," Cell (2025), DOI 10.1016/j.cell.2025.07.031
Live Science reporting with outside expert comment
GEN, ScienceDaily, Phys.org, Medical News Today